dorsaVi has inked a five-year sales agreement with Select Medical, opening access to over 1,900 US outpatient physical therapy centers for its FDA-approved motion analysis products. This follows a successful 18-month pilot validating clinical benefits in athlete rehabilitation.
- Five-year sales agreement with Select Medical in the US
- Access to 1,900+ outpatient physical therapy centers nationwide
- 18-month pilot confirmed clinical utility for rehabilitation and return-to-play
- No minimum purchase obligations under the agreement
- dorsaVi’s FDA-approved wearable sensor and Video AI technologies featured
A Strategic US Expansion
dorsaVi Ltd (ASX:DVL), an Australian innovator in motion analysis technology, has taken a significant step into the US healthcare market by signing a five-year sales agreement with Select Medical, one of the largest outpatient physical therapy providers in the country. This deal grants Select Medical’s extensive network of over 1,900 centers the option to purchase dorsaVi’s FDA-approved products starting September 2025.
Validating Clinical Impact Through Collaboration
The agreement follows an 18-month development pilot where dorsaVi’s technology was rigorously tested within Select Medical’s clinical environment. This pilot was crucial in ensuring that the wearable sensor and Video AI solutions met the practical needs of therapists, particularly in collecting precise clinical data to aid rehabilitation of injured athletes and support return-to-play decisions. The pilot’s success underscores the technology’s potential to enhance patient outcomes through objective movement assessment.
Technology That Bridges Innovation and Practicality
dorsaVi’s product suite includes sensor-based devices that provide gold-standard accuracy comparable to high-end biomechanics labs, alongside Video AI tools that enable rapid movement assessments without the need for sensors. This dual approach caters to a broad spectrum of clinical needs, from detailed biomechanical analysis to quick, accessible evaluations. The technology’s ability to deliver real-time, actionable insights positions it as a valuable asset for physical therapists aiming to optimize rehabilitation protocols.
Market Implications and Future Prospects
While the agreement does not bind Select Medical to minimum purchase volumes, it opens a substantial commercial channel for dorsaVi in the US, a market with significant demand for advanced rehabilitation technologies. The partnership also serves as a strong endorsement of dorsaVi’s clinical relevance and commercial viability. Looking ahead, the company’s ability to convert this opportunity into sustained sales growth will be a key focus for investors and industry watchers alike.
Bottom Line?
dorsaVi’s US partnership marks a pivotal moment, but actual sales uptake will reveal the true impact.
Questions in the middle?
- How quickly will Select Medical integrate dorsaVi products across its centers?
- What competitive responses might emerge in the US motion analysis market?
- Could this agreement lead to further partnerships or expansions in other clinical segments?